Skip to main content
SpringerLink
Log in

Toxicity in Patients

  • Chapter
  • First Online:
Polymyxin Antibiotics: From Laboratory Bench to Bedside

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1145))

Abstract

Polymyxin toxicity remains a significant concern that limits the clinical utility of this class of antibacterials for patient care. The most notable adverse event is the dose- and treatment-limiting nephrotoxicity that occurs in roughly 30–60% of patients receiving a systemic polymyxin. This chapter focuses on this adverse event with a detailed assessment of the incidence of, and risk factors for, polymyxin-associated nephrotoxicity. In particular, the text focuses on the impact of dose, serum concentrations, and polymyxin selection on nephrotoxicity. Additionally, less common, but clinically important adverse events are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Falagas ME, Kasiakou SK (2006) Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10(1):R27

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bosso JA, Liptak CA, Seilheimer DK, Harrison GM (1991) Toxicity of colistin in cystic fibrosis patients. DICP 25(11):1168–1170

    Article  CAS  PubMed  Google Scholar 

  3. Conway SP, Etherington C, Munday J et al (2000) Safety and efficacy of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis. Ann Pharmacother 34:1238–1242

    Article  CAS  PubMed  Google Scholar 

  4. Ledson MJ, Gallagher MJ, Cowperthwaite C et al (1998) Four years experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 12:592–594

    Article  CAS  PubMed  Google Scholar 

  5. Conway SP, Pond MN, Watson A et al (1997) Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 52:987–993

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Markou N, Apostolakos H, Koumoudiou C et al (2003) Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 7(5):R78–R83

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kallel H, Hergafi L, Bahloul M et al (2007) Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 33(7):1162–1167

    Article  CAS  PubMed  Google Scholar 

  8. Reina R, Estenssoro E, Sáenz G et al (2005) Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31(8):1058–1065

    Article  PubMed  Google Scholar 

  9. Petrosillo N, Chinello P, Proietti MF et al (2005) Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 11(8):682–683

    Article  CAS  PubMed  Google Scholar 

  10. Kasiakou SK, Michalopoulos A, Soteriades ES et al (2005) Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 49(8):3136–3146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Falagas ME, Rafailidis PI, Kasiakou SK et al (2006) Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 12(12):1227–1230

    Article  CAS  PubMed  Google Scholar 

  12. Falagas ME, Kasiakou SK, Kofteridis DP et al (2006) Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 25(9):596–599

    Article  CAS  PubMed  Google Scholar 

  13. Falagas ME, Rizos M, Bliziotis IA et al (2005) Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 5:1

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Falagas ME, Fragoulis KN, Kasiakou SK et al (2005) Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 26(6):504–507

    Article  CAS  PubMed  Google Scholar 

  15. Michalopoulos AS, Tsiodras S, Rellos K et al (2005) Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 11(2):115–121

    Article  CAS  PubMed  Google Scholar 

  16. Hartzell JD, Neff R, Ake J et al (2009) Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 48(12):1724–1728

    Article  CAS  PubMed  Google Scholar 

  17. Deryke CA, Crawford AJ, Uddin N, Wallace MR (2010) Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 54(10):4503–4505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Pogue JM, Lee J, Marchaim D et al (2011) Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53(9):879–884

    Article  CAS  PubMed  Google Scholar 

  19. Gauthier TP, Wolowich WR, Reddy A et al (2012) Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 56(5):2392–2396

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ko HJ, Jeon MH, Choo EJ et al (2011) Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 117(3):c284–c288

    Article  CAS  PubMed  Google Scholar 

  21. Elias LS, Konzen D, Krebs JM, Zavascki AP (2010) The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 65(10):2231–2237

    Article  CAS  PubMed  Google Scholar 

  22. Kvitko CH, Rigatto MH, Moro AL, Zavascki AP (2011) Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 66(1):175–179

    Article  CAS  PubMed  Google Scholar 

  23. Oliveira MS, Prado GV, Costa SF et al (2009) Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 65(4):431–434

    Article  CAS  PubMed  Google Scholar 

  24. Tuon FF, Rigatto MH, Lopes CK et al (2014) Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43(4):349–352

    Article  CAS  PubMed  Google Scholar 

  25. Mendes CA, Cordeiro JA, Burdmann EA (2009) Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann Pharmacother 43(12):1948–1955

    Article  CAS  PubMed  Google Scholar 

  26. Akajagbor DS, Wilson SL, Shere-Wolfe KD et al (2013) Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57(9):1300–1303

    Article  CAS  PubMed  Google Scholar 

  27. Esaian D, Dubrovskaya Y, Phillips M, Papadopoulos J (2012) Effectiveness and tolerability of a polymyxin B dosing protocol. Ann Pharmacother 46(3):455–456

    Article  PubMed  Google Scholar 

  28. Phe K, Lee Y, McDaneld PM et al (2014) In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 58(5):2740–2746

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Mostardeiro MM, Pereira CA, Marra AR et al (2013) Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients. Antimicrob Agents Chemother 57(3):1442–1446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ouderkirk JP, Nord JA, Turett GS, Kislak JW (2003) Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 47(8):2659–2662

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Holloway KP, Rouphael NG, Wells JB et al (2006) Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 40(11):1939–1945

    Article  CAS  PubMed  Google Scholar 

  32. Ramasubban S, Majumdar A, Das PS (2008) Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock. Indian J Crit Care Med 12(4):153–157

    Article  PubMed  PubMed Central  Google Scholar 

  33. Pastewski AA, Caruso P, Parris AR et al (2008) Parenteral polymyxin B use in patients with multidrug-resistant Gram-negative bacteremia and urinary tract infections: a retrospective case series. Ann Pharmacother 42(9):1177–1187

    Article  CAS  PubMed  Google Scholar 

  34. Sobieszczyk ME, Furuya EY, Hay CM et al (2004) Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 54(2):566–569

    Article  CAS  PubMed  Google Scholar 

  35. Kubin CJ, Ellman TM, Phadke V et al (2012) Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 65(1):80–87

    Article  PubMed  Google Scholar 

  36. Chan JD, Graves JA, Dellit TH (2010) Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med 25(6):343–348

    Article  PubMed  Google Scholar 

  37. Rattanaumpawan P, Ungprasert P, Thamlikitkul V (2011) Risk factors for colistin-associated nephrotoxicity. J Infect 62(2):187–190

    Article  PubMed  Google Scholar 

  38. Turkoglu M, Dizbay M, Ciftçi A et al (2012) Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction. Int J Antimicrob Agents 39(2):142–145

    Article  CAS  PubMed  Google Scholar 

  39. Dalfino L, Puntillo F, Mosca A et al (2012) High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 54(12):1720–1726

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Rocco M, Montini L, Alessandri E et al (2013) Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 17(4):R174.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Kalin G, Alp E, Coskun R et al (2012) Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother 18(6):872–877

    Article  CAS  PubMed  Google Scholar 

  42. Sorlí L, Luque S, Grau S et al (2013) Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 13:380

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Averbuch D, Horwitz E, Strahilevitz J et al (2013) Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients. Infection 41(5):991–997

    Article  CAS  PubMed  Google Scholar 

  44. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ et al (2003) Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36(9):1111–1118

    Article  CAS  PubMed  Google Scholar 

  45. Durakovic N, Radojcic V, Boban A et al (2011) Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med 50(9):1009–1013

    Article  CAS  PubMed  Google Scholar 

  46. Kim J, Lee KH, Yoo S, Pai H (2009) Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 34(5):434–438

    Article  CAS  PubMed  Google Scholar 

  47. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V (2007) Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 11(5):402–406

    Article  CAS  PubMed  Google Scholar 

  48. Cheng CY, Sheng WH, Wang JT et al (2010) Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 35(3):297–300

    Article  CAS  PubMed  Google Scholar 

  49. Levin AS, Barone AA, Penço J et al (1999) Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28(5):1008–1011

    Article  CAS  PubMed  Google Scholar 

  50. Doshi NM, Mount KL, Murphy CV (2011) Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 31(12):1257–1264

    Article  PubMed  Google Scholar 

  51. Petrosillo N, Giannella M, Antonelli M et al (2014) Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother 58(2):851–858

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Vicari G, Bauer SR, Neuner EA, Lam SW (2013) Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant Gram-negative bacteremia. Clin Infect Dis 56(3):398–404

    Article  CAS  PubMed  Google Scholar 

  53. Yılmaz GR, Baştuğ AT, But A et al (2013) Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant Gram-negative pathogens. J Infect Chemother 19(1):57–62

    Article  PubMed  CAS  Google Scholar 

  54. Sabuda DM, Laupland K, Pitout J et al (2008) Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol 19(6):413–418

    Article  PubMed  PubMed Central  Google Scholar 

  55. Lim SK, Lee SO, Choi SH et al (2011) The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci 26(3):325–331

    Article  PubMed  PubMed Central  Google Scholar 

  56. Gounden R, Bamford C, van Zyl-Smit R et al (2009) Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 9:26

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Falagas ME, Rafailidis PI, Ioannidou E et al (2010) Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 35(2):194–199

    Article  CAS  PubMed  Google Scholar 

  58. Santamaría C, Mykietiuk A, Temporiti E et al (2009) Nephrotoxicity associated with the use of intravenous colistin. Scand J Infect Dis 41(10):767–769

    Article  PubMed  Google Scholar 

  59. Pintado V, San Miguel LG, Grill F et al (2008) Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria. J Infect 56(3):185–190

    Article  PubMed  Google Scholar 

  60. Paul M, Bishara J, Levcovich A et al (2010) Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 65(5):1019–1027

    Article  CAS  PubMed  Google Scholar 

  61. Montero M, Horcajada JP, Sorlí L et al (2009) Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 37(5):461–465

    Article  CAS  PubMed  Google Scholar 

  62. Bassetti M, Repetto E, Righi E et al (2008) Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 61(2):417–420

    Article  CAS  PubMed  Google Scholar 

  63. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE (2008) Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 56(6):432–436

    Article  PubMed  Google Scholar 

  64. Karnik ND, Sridharan K, Jadhav SP et al (2013) Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection. Eur J Clin Pharmacol 69(7):1429–1436

    Article  CAS  PubMed  Google Scholar 

  65. Markou N, Markantonis SL, Dimitrakis E et al (2008) Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 30(1):143–151

    Article  CAS  PubMed  Google Scholar 

  66. Nelson BC, Eiras DP, Gomez-Simmonds A et al (2015) Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. Antimicrob Agents Chemother 59(11):7000–7006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Rigatto MH, Behle TF, Falci DR et al (2015) Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother 70(5):1552–1557

    Article  CAS  PubMed  Google Scholar 

  68. Rigatto MH, Oliveira MS, Perdigão-Neto LV et al (2016) Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother 60(4):2443–2449

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Vardakas KZ, Falagas ME (2017) Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents 49(2):233–238

    Article  CAS  PubMed  Google Scholar 

  70. Crass RL, Rutter WC, Burgess DR et al (2017) Nephrotoxicity in patients with or without cystic fibrosis treated with polymyxin B compared to colistin. Antimicrob Agents Chemother 61(4). pii: e02329-16

    Google Scholar 

  71. Garonzik SM, Li J, Thamlikitkul V et al (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55(7):3284–3294

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Forrest A, Garonzik SM, Thamlikitkul V et al (2017) Pharmacokinetic/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients. Antimicrob Agents Chemother 61(11). pii: e01367-17

    Google Scholar 

  73. Shields RK, Anand R, Clarke LG et al (2017) Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria. PLoS One 12(3):e0173286

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Yousef JM, Chen G, Hill PA, Nation RL, Li J (2012) Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 67(2):452–459

    Article  CAS  PubMed  Google Scholar 

  75. Sirijatuphat R, Limmahakhun S, Sirivatanauksorn V et al (2015) Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity. Antimicrob Agents Chemother 59(6):3224–3232

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Dalfino L, Puntillo F, Ondok MJ et al (2015) Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study. Clin Infect Dis 61(12):1771–1777

    Article  CAS  PubMed  Google Scholar 

  77. Wallace SJ, Li J, Nation RL et al (2008) Subacute toxicity of colistin methanesulfonate in rats: comparisons of various intravenous dosage regimens. Antimicrob Agents Chemother 52(3):1159–1161

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Bergen PJ, Li J, Nation RL et al (2008) Comparison of once-, twice, and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 61:636–642

    Article  CAS  PubMed  Google Scholar 

  79. Abdelraouf K, Chang KT, Yin T et al (2014) Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother 58(7):4200–4202

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Linden PK, Kusne S, Coley K et al (2003) Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 37(11):e154–e160

    Article  CAS  PubMed  Google Scholar 

  81. Weinstein L, Doan TL, Smith MA (2009) Neurotoxicity in patients treated with intravenous polymyxin B: two case reports. Am J Health Syst Pharm 66(4):345–347

    Article  CAS  PubMed  Google Scholar 

  82. Knueppel RC, Rahimian J (2007) Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B. Clin Infect Dis 45(1):136–138

    Article  PubMed  Google Scholar 

  83. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D et al (2012) Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis 14(2):198–205

    Article  CAS  PubMed  Google Scholar 

  84. Zavascki AP, Manfro RC, Maciel RA, Falci DR (2015) Head and neck hyperpigmentation probably associated with polymyxin B therapy. Ann Pharmacother 49(10):1171–1172

    Article  CAS  PubMed  Google Scholar 

  85. Zavascki AP, Schuster LF, Duquia RP (2016) Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation. Int J Antimicrob Agents 48(5):579–580

    Article  CAS  PubMed  Google Scholar 

  86. Domínguez-Ortega J, Manteiga E, Abad-Schilling C et al (2007) Induced tolerance to nebulized colistin after severe reaction to the drug. J Investig Allergol Clin Immunol 17(1):59–61

    PubMed  Google Scholar 

  87. Rattanaumpawan P, Lorsutthitham J, Ungprasert P et al (2010) Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 65(12):2645–2649

    Article  CAS  PubMed  Google Scholar 

  88. FDA alert 06.28.2007. Accessed from https://wayback.archiveit.org/7993/20170406044905/ https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM124894.pdf. Last access 19 Jun 2019

  89. Pereira GH, Muller PR, Levin AS (2007) Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 58:235–240

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Services, Sinai-Grace Hospital, Detroit Medical Center, Detroit, MI, USA

    Jason M. Pogue

  2. Department of Pharmacological and Pharmaceutical Sciences, Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA

    Vincent H. Tam

Authors
  1. Jason M. Pogue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincent H. Tam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jason M. Pogue .

Editor information

Editors and Affiliations

  1. Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University, Clayton Campus, Melbourne, VIC, Australia

    Jian Li

  2. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville Campus, Melbourne, VIC, Australia

    Roger L. Nation

  3. Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA

    Keith S. Kaye

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pogue, J.M., Tam, V.H. (2019). Toxicity in Patients. In: Li, J., Nation, R., Kaye, K. (eds) Polymyxin Antibiotics: From Laboratory Bench to Bedside. Advances in Experimental Medicine and Biology, vol 1145. Springer, Cham. https://doi.org/10.1007/978-3-030-16373-0_17

Download citation

Publish with us

Policies and ethics

Search

Navigation